Trial reportThe Journal of clinical investigation2020
Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption.
Trial report in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.Frontiers in immunology · 2024Trial
- Immune activation during broadly neutralizing antibody-mediated HIV suppression prior to post-intervention control.bioRxiv : the preprint server for biology · 2026Article
- Early immune responses anticipate HIV rebound and precede viral control.bioRxiv : the preprint server for biology · 2026Article
- HIV Virion Capturing Liposomes for Therapeutic Vaccination.bioRxiv : the preprint server for biology · 2025Article
- Antiviral Monocytes Increase Prior to Detectable HIV-1 Rebound Viremia.The Journal of infectious diseases · 2025Article
- Plasmacytoid dendritic cells are dispensable or detrimental in murine systemic or respiratory viral infections.Nature immunology · 2025Article
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- Dynamic changes in immune cell subsets in blood and lymph node over the course of acute HIV infection.Journal of virus eradication · 2025Article
- The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond.Cellular & molecular immunology · 2024Review
- Immunologic and Virologic Parameters Associated With Human Immunodeficiency Virus (HIV) DNA Reservoir Size in People With HIV Receiving Antiretroviral Therapy.The Journal of infectious diseases · 2024Article
- Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8Nature communications · 2024Article
- Prevention, treatment and cure of HIV infection.Nature reviews. Microbiology · 2023Review
- Current perspective on biological properties of plasmacytoid dendritic cells and dysfunction in gut.Immunity, inflammation and disease · 2023Review
- Interleukin 18 (IL-18) and IL-3 in Extracellular Vesicles: Biomarkers for Durable Elite Control of HIV-1.The Journal of infectious diseases · 2023Article
- HIV-Host Cell Interactions.Cells · 2023Review
- Advances in HIV Research Using Mass Cytometry.Current HIV/AIDS reports · 2023Review
- The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy.European journal of medical research · 2023Article
- HIV-1 infection enhances innate function andLife science alliance · 2022Article
- Engaging innate immunity in HIV-1 cure strategies.Nature reviews. Immunology · 2022Review
- Viral and Host Biomarkers of HIV Remission Post Treatment Interruption.Current HIV/AIDS reports · 2022Review
Corrections and comments
- Commented on by
Authors and funding
26 authors at 8 institutions in 4 countries.
Funding
Abstract
Plasmacytoid dendritic cells (pDCs) are robust producers of IFNα and one of the first immune cells to respond to SIV infection. To elucidate responses to early HIV-1 replication, we studied blood pDCs in 29 HIV-infected participants who initiated antiretroviral therapy during acute infection and underwent analytic treatment interruption (ATI). We observed an increased frequency of partially activated pDCs in the blood before detection of HIV RNA. Concurrent with peak pDC frequency, we detected a transient decline in the ability of pDCs to produce IFNα in vitro, which correlated with decreased phosphorylation of IFN regulatory factory 7 (IRF7) and NF-κB. The levels of phosphorylated IRF7 and NF-κB inversely correlated with plasma IFNα2 levels, implying that pDCs were refractory to in vitro stimulation after IFNα production in vivo. After ATI, decreased expression of IFN genes in pDCs inversely correlated with the time to viral detection, suggesting that pDC IFN loss is part of an effective early immune response. These data from a limited cohort provide a critical first step in understanding the earliest immune response to HIV-1 and suggest that changes in blood pDC frequency and function can be used as an indicator of viral replication before detectable plasma viremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.